<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "8: Increasing ", fill: "#002147"},
{source: "8: Increasing ", target: "8: activities", fill: "#002147"},
{source: "8: activities", target: "8: effectively", fill: "#002147"},
{source: "8: effectively", target: "8: manufacturing", fill: "#002147"},
{source: "8: manufacturing", target: "8: competitors", fill: "#002147"},
{source: "8: Increasing ", target: "11: veterinary market", fill: "#e5e4e2"},
{source: "11: veterinary market", target: "11: derived primarily by", fill: "#e5e4e2"},
{source: "11: derived primarily by", target: "11: distributors", fill: "#e5e4e2"},
{source: "11: distributors", target: "11: ultimate user", fill: "#e5e4e2"},
{source: "11: veterinary market", target: "12: While ", fill: "#ffc0cb"},
{source: "12: While ", target: "12: better able", fill: "#ffc0cb"},
{source: "12: better able", target: "12: predict sales", fill: "#ffc0cb"},
{source: "12: predict sales", target: "12: reagent discs as", fill: "#ffc0cb"},
{source: "12: reagent discs as", target: "12: discs primarily", fill: "#ffc0cb"},
{source: "12: discs primarily", target: "12: use with blood chemistry analyzers", fill: "#ffc0cb"},
{source: "12: use with blood chemistry analyzers", target: "12: blood chemistry", fill: "#ffc0cb"},
{source: "12: blood chemistry", target: "12: chemistry", fill: "#ffc0cb"},
{source: "12: chemistry", target: "12: analyzers", fill: "#ffc0cb"},
{source: "12: analyzers", target: "12: generally", fill: "#ffc0cb"},
{source: "12: generally", target: "12: predict with", fill: "#ffc0cb"},
{source: "12: predict with", target: "12: certainty sales", fill: "#ffc0cb"},
{source: "12: certainty sales", target: "12: typically sell", fill: "#ffc0cb"},
{source: "12: While ", target: "99: Internationally ", fill: "#addfad"},
{source: "99: Internationally ", target: "99: few distributors", fill: "#addfad"},
{source: "99: few distributors", target: "99: veterinary diagnostic markets which", fill: "#addfad"},
{source: "99: veterinary diagnostic markets which", target: "99: one distributor", fill: "#addfad"},
{source: "99: one distributor", target: "99: in September ", fill: "#addfad"},
{source: "99: in September ", target: "99: Japanese ", fill: "#addfad"},
{source: "99: Japanese ", target: "99: regulatory agency", fill: "#addfad"},
{source: "99: regulatory agency", target: "99: medical reagent", fill: "#addfad"},
{source: "99: medical reagent", target: "99: system as well as", fill: "#addfad"},
{source: "99: system as well as", target: "99: veterinary reagent discs", fill: "#addfad"},
{source: "99: veterinary reagent discs", target: "99: system with", fill: "#addfad"},
{source: "99: system with", target: "99: products containing", fill: "#addfad"},
{source: "99: products containing", target: "99: respective country", fill: "#addfad"},
{source: "99: Internationally ", target: "160: Current Good Manufacturing Practice ", fill: "#007fbf"},
{source: "160: Current Good Manufacturing Practice ", target: "160: requirements", fill: "#007fbf"},
{source: "160: requirements", target: "160: Quality System Regulation", fill: "#007fbf"},
{source: "160: Current Good Manufacturing Practice ", target: "164: State of California Food and Drug Branch ", fill: "#bc8f8f"},
{source: "164: State of California Food and Drug Branch ", target: "164: manufacturing facility", fill: "#bc8f8f"},
{source: "164: manufacturing facility", target: "164: compliance status based on", fill: "#bc8f8f"},
{source: "164: compliance status based on", target: "164: regulations", fill: "#bc8f8f"},
{source: "164: regulations", target: "164: Good Manufacturing Practices ", fill: "#bc8f8f"},
{source: "164: State of California Food and Drug Branch ", target: "START_HERE", fill: "#bc8f8f"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_female_fitness_and_figure_competitors">List of female fitness and figure competitors</a></td>
      <td>This is a list of female fitness and figure competitors.\n\n\n== A ==\nJelena Abbou\n\n\n== B ==\nLauren Beckham\nAlexandra Béres\nSharon Bruneau\n\n\n== C ==\nNatalie Montgomery-Carroll\nJen Cassetty\nKim Chizevsky\nSusie Curry\n\n\n== D ==\nDebbie Dobbins\nNicole Duncan\n\n\n== E ==\nJamie Eason\nAlexis Ellis\n\n\n== F ==\nAmy Fadhli\nJaime Franklin\n\n\n== G ==\nAdela García \nConnie Garner\nElaine Goodlad\nTracey Greenwood\nOksana Grishina\n\n\n== H ==\nMallory Haldeman\nVanda Hădărean\nJen Hendershott\nSoleivi Hernandez\nApril Hunter\n\n\n== I ==\n\n\n== J ==\nTsianina Joelson\n\n\n== K ==\nAdria Montgomery-Klein\nAshley Kaltwasser\n\n\n== L ==\nLauren Lillo\nMary Elizabeth Lado\nTammie Leady\nJennifer Nicole Lee\nAmber Littlejohn\nJulie Lohre\nJenny Lynn\n\n\n== M ==\nTimea Majorová\nLinda Maxwell\nDavana Medina\nJodi Leigh Miller\nChisato Mishima\n\n\n== N ==\nKim Nielsen\n\n\n== O ==\n\n\n== P ==\nVicky Pratt\nElena Panova\nChristine Pomponio-Pate\nCathy Priest\n\n\n== Q ==\n\n\n== R ==\nMaite Richert\nCharlene Rink\nKelly Ryan\n\n\n== S ==\nErin Stern\nCarol Semple-Marzetta\nKrisztina Sereny\nTrish Stratus (Patricia Anne Stratigias)\n\n\n== T ==\nKristi Tauti\nJennifer Thomas\n\n\n== U ==\n\n\n== V ==\nLisa Marie Varon\n\n\n== W ==\nLatisha Wilder\nTorrie Wilson\nLyen Wong\nJenny Worth\nNicole Wilkins\n\n\n== Y ==\n\n\n== Z ==\nMarietta Žigalová\nMalika Zitouni\n\n\n== See also ==\nList of female bodybuilders\n\n\n== References ==\nThere has been a rise in the number of women wanting to compete as fitness models.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hartford_Distributors_shooting">Hartford Distributors shooting</a></td>
      <td>The Hartford Distributors shooting was a mass shooting that occurred on August 3, 2010, in Manchester, Connecticut, United States. The location of the crime was a warehouse owned by Hartford Distributors, a beer distribution company.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Brewers'_Distributor">Brewers' Distributor</a></td>
      <td>Brewers' Distributor Ltd. (BDL) is a Canadian company that distributes beer throughout the four western provinces and three northern territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/General_Film_Distributors">General Film Distributors</a></td>
      <td>General Film Distributors (GFD), later known as J. Arthur Rank Film Distributors and Rank Film Distributors Ltd., was a British film distribution company based in London. It was active between 1935 and 1996, and from 1937 it was part of the Rank Organisation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Titan_Distributors">Titan Distributors</a></td>
      <td>Titan Distributors was a British comic book distributor which existed from 1978 to 1993, when it was acquired by a larger U.S. distributor. Operated by Nick Landau, Mike Lake, and Mike Luckman, Titan Distributors supplied comics, science fiction, and other genre products to retailers all over the United Kingdom.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Quality_Distributors">Quality Distributors</a></td>
      <td>Quality Distributors FC are a professional association football (soccer) club in Guam. They play in the Guam Soccer League.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_film_distributors_by_country">List of film distributors by country</a></td>
      <td>This is a list of motion picture distributors, past and present, sorted alphabetically by country.\n\n\n== Albania ==\nConstantin Film\nUnited International Pictures\n\n\n== Argentina ==\nBuena Vista International\nWarner Bros.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sony_Pictures_Motion_Picture_Group">Sony Pictures Motion Picture Group</a></td>
      <td>Sony Pictures Entertainment Motion Picture Group (commonly known as Sony Pictures Motion Picture Group, formerly known as the Columbia TriStar Motion Picture Group until 2013, and abbreviated as SPMPG) is a division of Sony Pictures Entertainment to manage its motion picture operations. It was launched in 1998 by integrating the businesses of Columbia Pictures Industries, Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Isopropyl_alcohol">Isopropyl alcohol</a></td>
      <td>Isopropyl alcohol (IUPAC name propan-2-ol and also called isopropanol or 2-propanol) is a colorless, flammable chemical compound (chemical formula CH3CHOHCH3) with a strong odor. As an isopropyl group linked to a hydroxyl group, it is the simplest example of a secondary alcohol, where the alcohol carbon atom is attached to two other carbon atoms.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lovibond_comparator">Lovibond comparator</a></td>
      <td>The Lovibond comparator is an example of a colorimeter made in Britain by The Tintometer Ltd.  It was invented in the 19th century by Joseph Williams Lovibond and updated versions are still available.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gas_bubbler">Gas bubbler</a></td>
      <td>A gas bubbler  is a piece of laboratory glassware which consists of a glass bulb filled with a small amount of fluid — usually mineral or silicone oil, less commonly mercury. The inlet to the bulb is connected to a ground glass joint, while the outlet is vented to the air.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Windows_Preinstallation_Environment">Windows Preinstallation Environment</a></td>
      <td>Windows Preinstallation Environment (also known as Windows PE and WinPE) is a lightweight version of Windows used for the deployment of PCs, workstations, and servers, or troubleshooting an operating system while it is offline. It is intended to replace MS-DOS boot disks and can be booted via USB flash drive, PXE, iPXE, CD-ROM, or hard disk.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Instant_film">Instant film</a></td>
      <td>Instant film is a type of photographic film that was introduced by Polaroid Corporation to produce a visible image within minutes or seconds of the photograph's exposure. The film contains the chemicals needed for developing and fixing the photograph, and the camera exposes and initiates the developing process after a photo has been taken.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Turbidity">Turbidity</a></td>
      <td>Turbidity is the cloudiness or haziness of a fluid caused by large numbers of individual particles that are generally invisible to the naked eye, similar to smoke in air. The measurement of turbidity is a key test of water quality.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cyanine">Cyanine</a></td>
      <td>Cyanines, also referred to as tetramethylindo(di)-carbocyanines are a synthetic dye family belonging to the polymethine group.  Although the name derives etymologically from terms for shades of blue, the cyanine family covers the electromagnetic spectrum from near IR to UV. \nChemically, cyanines are a conjugated system between two nitrogen atoms; in each resonance structure, exactly one nitrogen atom is oxidized to an iminium.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Queen's_Regulations">Queen's Regulations</a></td>
      <td>The Queen's Regulations (first published in 1731 and known as the King's Regulations when the monarch is a king) is a collection of orders and regulations in force in the Royal Navy, British Army, Royal Air Force, and Commonwealth Realm Forces (where the same person as on the British throne is also their separate head of state), forming guidance for officers of these armed services in all matters of discipline and personal conduct. Originally, a single set of regulations were published in one volume.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Codes,_Rules_and_Regulations">New York Codes, Rules and Regulations</a></td>
      <td>The New York Codes, Rules and Regulations (NYCRR) contains New York state rules and regulations. The NYCRR is officially compiled by the New York State Department of State's Division of Administrative Rules.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ABAXIS INC      Item 1A  Risk Factors                 Our <font color="blue">future performance</font> is subject to a number of risks</td>
    </tr>
    <tr>
      <td>If any of     the <font color="blue">following risks actually</font> occur, our business could be harmed and the     <font color="blue">trading price</font> of our <font color="blue"><font color="blue">common stock</font> could decline</font></td>
    </tr>
    <tr>
      <td>When  used  in  these <font color="blue">risk factors</font>, the words “anticipates,”     “believes,” “expects,” “intends,” “plans,” “future,” and similar <font color="blue">expressions</font>     identify  forward-looking statements</td>
    </tr>
    <tr>
      <td>Our actual results <font color="blue">could differ</font>     <font color="blue"><font color="blue">materially</font> from</font> those that we project in the forward-looking statements as a     result of factors that we have <font color="blue">set forth throughout</font> this <font color="blue">document as well as</font>     factors of which we are currently not aware</td>
    </tr>
    <tr>
      <td>We Have Only Recently Become Consistently Profitable; We Must Increase Sales     Of Our Piccolo And VetScan DXS Products To Maintain Profitability                  We  have  not  recognized  a <font color="blue">net loss attributable</font> to common     <font color="blue">shareholders</font>  in the <font color="blue">last twelve fiscal quarters</font> ended March 31, 2006</td>
    </tr>
    <tr>
      <td>However,  as of March 31, 2006, we have <font color="blue">cumulative net losses</font> of dlra25dtta5     million</td>
    </tr>
    <tr>
      <td>Our ability to be <font color="blue">consistently profitable will depend</font>, in part, on     our ability to increase our <font color="blue">sales volumes</font> of our <font color="blue">Piccolo and VetScan </font>DXS     products</td>
    </tr>
    <tr>
      <td><font color="blue">Increasing </font>the sales volume of our <font color="blue">products will</font> depend upon our     ability to:                                         13     ______________________________________________________________________                                         •                         continue to develop our products;                                             •                    increase our sales and marketing <font color="blue">activities</font>;                                             •                <font color="blue"><font color="blue">effective</font>ly</font> manage our <font color="blue">manufacturing</font> <font color="blue">activities</font>; and                                             •            <font color="blue"><font color="blue">effective</font>ly</font> compete against current and future <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to <font color="blue">successfully increase</font>     our <font color="blue">sales volumes</font> of our products to achieve <font color="blue">sustained profitability</font></td>
    </tr>
    <tr>
      <td>We Are Not Able To Predict Sales In Future Quarters And A Number Of Factors     Affect Our Periodic Results                  We  are  not  able to <font color="blue"><font color="blue">accurately</font> predict</font> our sales in future     quarters</td>
    </tr>
    <tr>
      <td>Our revenue in the <font color="blue"><font color="blue">veterinary</font> market</font> are <font color="blue">derived primarily by</font>     selling to <font color="blue"><font color="blue">distributor</font>s</font> who resell our products to the <font color="blue">ultimate user</font></td>
    </tr>
    <tr>
      <td><font color="blue">While     </font>we are <font color="blue">better able</font> to <font color="blue">predict sales</font> of our <font color="blue"><font color="blue">reagent disc</font>s</font>, as we sell these     <font color="blue">discs primarily</font> for <font color="blue">use with <font color="blue">blood <font color="blue">chemistry</font></font> <font color="blue">analyzers</font></font> that we sold in prior     periods, we <font color="blue">generally</font> are unable to <font color="blue">predict with</font> much <font color="blue">certainty sales</font> of our     blood  <font color="blue">chemistry</font>  <font color="blue">analyzers</font>,  as we <font color="blue">typically sell</font> our <font color="blue">blood <font color="blue">chemistry</font></font>     <font color="blue">analyzers</font> to new users</td>
    </tr>
    <tr>
      <td>Accordingly, our sales in any <font color="blue">one quarter</font> are not     <font color="blue">indicative</font> of our sales in any <font color="blue">future period</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font> operate with limited order backlog, because we ship     our <font color="blue">products shortly</font> after we receive the <font color="blue">orders from</font> our customers</td>
    </tr>
    <tr>
      <td>As a     result, our product sales in any quarter are <font color="blue">generally</font> <font color="blue">dependent</font> on orders     that we receive and ship in that quarter</td>
    </tr>
    <tr>
      <td>We base our expense levels, which     are  to a large extent fixed, in part on our <font color="blue">expectations as</font> to future     revenues</td>
    </tr>
    <tr>
      <td>We may be unable to reduce our spending in a <font color="blue">timely manner</font> to     compensate for any <font color="blue">unexpected revenue shortfall</font></td>
    </tr>
    <tr>
      <td>As a result, any such     shortfall would <font color="blue">immediately</font> <font color="blue">materially</font> and <font color="blue">adversely</font> impact our operating     results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Historically,  we  have experienced a decrease in our sales,     <font color="blue">especially</font> in Europe, in our second and <font color="blue">third quarter</font>s ending <font color="blue">in <font color="blue">September </font></font>    and <font color="blue">December </font>of each year, which we believe is due to seasonal patterns in     the decision making processes to acquire our products</td>
    </tr>
    <tr>
      <td>Accordingly, we     believe that period to <font color="blue">period comparisons</font> of our results of <font color="blue">operations</font> are     not <font color="blue">necessarily meaningful</font></td>
    </tr>
    <tr>
      <td>In the     future, we anticipate our periodic operating results to vary <font color="blue">significantly</font>     depending  on,  but not limited to, a number of factors, including, in     addition to those <font color="blue">factors discussed elsewhere</font> in this section:                                         •              <font color="blue">new product <font color="blue">announcements</font></font> made by us or our <font color="blue">competitors</font>;                                             •         changes in our <font color="blue">pricing structures</font> or the <font color="blue">pricing structures</font> of our                                  <font color="blue">competitors</font>;                                             •    our ability to develop, introduce and <font color="blue">market new products on</font> a <font color="blue">timely basis</font>;                                             •     our <font color="blue">manufacturing</font> <font color="blue">capacities</font> and our ability to increase the scale of these                                  <font color="blue">capacities</font>;                                             •       the mix of <font color="blue">product sales between</font> our <font color="blue">blood <font color="blue">chemistry</font></font> analyzer and our                             <font color="blue"><font color="blue">reagent disc</font> products</font>;                                             •                the amount we <font color="blue">spend on research</font> and <font color="blue">development</font>; and                                             •                              changes in our strategy</td>
    </tr>
    <tr>
      <td>We Could Fail to Achieve Anticipated Revenue If The Market Does Not Accept     Our Products                 Our  core  compact  <font color="blue">blood <font color="blue">chemistry</font></font> analyzer product differs     substantially from current <font color="blue">blood <font color="blue">chemistry</font></font> <font color="blue">analyzers</font> on the market</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">primary competition</font> is <font color="blue">from centralized <font color="blue">laboratories</font></font> that offer a greater     number of tests than our products, but do so at a <font color="blue">greater cost</font> and requiring     more time</td>
    </tr>
    <tr>
      <td>We <font color="blue">also <font color="blue">compete with</font></font> other point-of-care <font color="blue">analyzers</font> that cost     more,  require  more  maintenance and offer a <font color="blue">narrower range</font> of tests</td>
    </tr>
    <tr>
      <td>However, these point-of-care <font color="blue">analyzers</font> are <font color="blue">generally</font> marketed by larger     <font color="blue">companies which</font> have <font color="blue">greater resources</font> for sales and marketing, in addition     to a recognized brand name and <font color="blue">established <font color="blue">distribution</font> <font color="blue">relationships</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Historically </font>we have marketed our VetScan DXS <font color="blue">system through both</font>     direct  sales and <font color="blue"><font color="blue">distribution</font> channels</font> to <font color="blue">veterinarians</font></td>
    </tr>
    <tr>
      <td>Although we     believe that in our <font color="blue">targeted markets</font>, our <font color="blue"><font color="blue">reagent disc</font> products</font> provide a     <font color="blue">sufficient breadth</font> of test menus, we continue to develop <font color="blue">new animal blood</font>     tests  and we cannot be assured that the tests will be <font color="blue">accepted by</font> the     <font color="blue"><font color="blue">veterinary</font> market</font></td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________                 In the <font color="blue">human <font color="blue">medical market</font></font>, we have <font color="blue">relatively</font> limited experience     in large scale sales of our Piccolo analyzer</td>
    </tr>
    <tr>
      <td>Although we believe that our     blood <font color="blue">analyzers</font> offer consumers many <font color="blue">advantages</font>, including <font color="blue">according</font> to our     analyses  substantial <font color="blue">cost savings</font>, in terms of the <font color="blue">actual product</font> and     <font color="blue">implementation</font> of it <font color="blue">procedurally</font>, these <font color="blue">advantages</font> involve changes to     current standard practices, such as using large <font color="blue">clinical <font color="blue">laboratories</font></font>, that     will require changes in both the procedures and mindset of <font color="blue">care providers</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">human <font color="blue">medical market</font></font> in particular is highly regulated, structured,     <font color="blue">difficult</font> to penetrate and <font color="blue">often slow</font> to <font color="blue">adopt new product offerings</font></td>
    </tr>
    <tr>
      <td>If we     are unable to convince large numbers of medical clinics, hospitals and other     point-of-care <font color="blue">environments</font> of the benefits of our products, we will suffer     lost sales and could fail to achieve anticipated revenue</td>
    </tr>
    <tr>
      <td>We Are Dependent Upon Our Profitability, And If We Cannot Remain Profitable     We May Need Additional Funding In The Future And These Funds May Not Be     Available To Us                 We believe that our existing capital resources, available line of     credit  and anticipated <font color="blue">revenue from</font> the sales of our <font color="blue">products will</font> be     adequate  to  satisfy  our  currently  planned operating and financial     <font color="blue"><font color="blue">requirements</font> through</font> March 31, 2007, although no assurances can be given</td>
    </tr>
    <tr>
      <td>The terms of our line of credit contain a number of <font color="blue">covenants concerning</font>     <font color="blue">financial tests</font> that we must meet, and these tests are more <font color="blue">fully explained</font>     herein  under the subheading, “Management’s Discussion and Analysis of     <font color="blue">Financial Condition and Results of Operations</font></td>
    </tr>
    <tr>
      <td>”                  Further, we expect to <font color="blue">incur incremental <font color="blue">additional</font> costs</font> to     support our future <font color="blue">operations</font>, including:                                         •       <font color="blue">further commercialization</font> of our products and <font color="blue">development</font> of new test  methods to allow us to <font color="blue">further penetrate</font> the <font color="blue">human <font color="blue"><font color="blue">diagnostic</font> market</font></font> and the                         <font color="blue"><font color="blue">veterinary</font> <font color="blue"><font color="blue">diagnostic</font> market</font></font>;                                             •       our need to acquire <font color="blue">capital equipment</font> for our <font color="blue">manufacturing</font> <font color="blue">facilities</font>,    which includes the <font color="blue">ongoing costs</font> related to the continuing <font color="blue">development</font> of                        our current and <font color="blue">future products</font>;                                             •       research and <font color="blue">design costs</font> related to the continuing <font color="blue">development</font> of our                        current and <font color="blue">future products</font>; and                                             •       <font color="blue">additional</font> pre-clinical testing and <font color="blue">clinical trials</font> for our current and                                <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>To the extent that our existing resources and anticipated revenue     from the sale of our products are insufficient to fund our <font color="blue">activities</font> or if     we are unable to meet the financial covenants of our line of credit, we may     have  to raise <font color="blue">additional</font> funds from the issuance of public or private     securities</td>
    </tr>
    <tr>
      <td>We may not be able to raise <font color="blue">additional</font> funding, or if we are able     to, we may not be able to <font color="blue">raise funding on</font> acceptable terms</td>
    </tr>
    <tr>
      <td>We may also     dilute then-existing <font color="blue">shareholders</font> if we raise <font color="blue">additional</font> funds by issuing     <font color="blue">new equity securities</font></td>
    </tr>
    <tr>
      <td>Alternately, we may have to <font color="blue">relinquish rights</font> to     certain of our <font color="blue">technologies</font>, products and/or sales territories if we are     required to obtain funds through <font color="blue">arrangements</font> with collaborative partners</td>
    </tr>
    <tr>
      <td>If we are unable to raise needed funds, we may be required to curtail our     <font color="blue">operations</font>  <font color="blue">significantly</font></td>
    </tr>
    <tr>
      <td>This would <font color="blue">materially</font> <font color="blue">adversely</font> affect our     operating results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We Rely On Patents And Other Proprietary Information, The Loss Of Any Would     Negatively Affect Our Business                 As of March 31, 2006, 35 patent <font color="blue"><font color="blue">application</font>s</font> have been filed on     behalf of Abaxis with the <font color="blue"><font color="blue"><font color="blue">United States</font> </font>Patent </font>and Trademark Office, of     which  29  have  been  issued</td>
    </tr>
    <tr>
      <td>Additionally,  we  have <font color="blue">filed several</font>     <font color="blue"><font color="blue">international</font> patent <font color="blue"><font color="blue">application</font>s</font> covering</font> the same subject matter as our     domestic  <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>The  patent  position  of any medical device     <font color="blue"><font color="blue">manufacture</font>r</font>, including Abaxis, is uncertain and <font color="blue">may involve complex legal</font>     and factual issues</td>
    </tr>
    <tr>
      <td>Consequently, we may not be issued any <font color="blue">additional</font>     patents, either domestically or <font color="blue"><font color="blue">international</font>ly</font></td>
    </tr>
    <tr>
      <td>Furthermore, our patents     may not <font color="blue">provide significant <font color="blue">proprietary</font> protection</font> because there is a chance     that they will be <font color="blue">circumvented</font> or invalidated</td>
    </tr>
    <tr>
      <td>We cannot be certain that we     were the first creator of the <font color="blue">inventions</font> covered by our <font color="blue">issued patents</font> or     pending  patent <font color="blue"><font color="blue">application</font>s</font>, or that we were the first to <font color="blue">file patent</font>     <font color="blue"><font color="blue">application</font>s</font> for these <font color="blue">inventions</font>, because (1) the <font color="blue"><font color="blue"><font color="blue">United States</font> </font>Patent </font>and     <font color="blue">Trademark Office </font>maintains all patent <font color="blue"><font color="blue">application</font>s</font> that are not filed in any     <font color="blue">foreign jurisdictions</font> in <font color="blue">secrecy until</font> it issues the patents (unless a     patent  <font color="blue">application</font>  owner  files  a  request for <font color="blue">publication</font>) and (2)     <font color="blue">publication</font>s of <font color="blue">discoveries</font> in the scientific or <font color="blue">patent literature tend</font> to     lag behind actual <font color="blue">discoveries</font> by several months</td>
    </tr>
    <tr>
      <td>We may have to <font color="blue">participate</font>     in interference <font color="blue">proceedings</font>, which are <font color="blue">proceedings</font> in front of the United     States  Patent and Trademark Office, to determine who will be issued a     patent</td>
    </tr>
    <tr>
      <td>These <font color="blue">proceedings</font> could be costly and could be <font color="blue">decided against us</font></td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________                 We also rely upon copyrights, trademarks and <font color="blue">unpatented trade</font>     secrets</td>
    </tr>
    <tr>
      <td>Others  may  <font color="blue">in<font color="blue">dependent</font>ly</font> develop <font color="blue">substantially equivalent</font>     <font color="blue">proprietary</font> information and <font color="blue">techniques</font> that <font color="blue">would undermine</font> our <font color="blue">proprietary</font>     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue">others may gain access</font> to our <font color="blue">trade secrets</font> or     disclose <font color="blue">such technology</font></td>
    </tr>
    <tr>
      <td>Although we require our employees, consultants     and  advisors  to  execute  <font color="blue">agreements</font> that require that our corporate     information  be  kept  <font color="blue">confidential</font>  and  that any <font color="blue">inventions</font> by these     <font color="blue">individuals</font> are property of Abaxis, there can be no assurance that these     <font color="blue">agreements</font> will provide meaningful protection or <font color="blue">adequate remedies</font> for our     trade  secrets  in the event of <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> of such     information</td>
    </tr>
    <tr>
      <td>The <font color="blue">unauthorized dissemination</font> of our <font color="blue">confidential</font> information     <font color="blue">would negatively impact</font> our business</td>
    </tr>
    <tr>
      <td>We Continue to Develop Our Marketing And Distribution Experience In the     Human Diagnostic Market                  Although we have gained experience marketing our VetScan DXS     <font color="blue">system products</font> in the <font color="blue"><font color="blue">veterinary</font> <font color="blue"><font color="blue">diagnostic</font> market</font></font>, we have limited sales,     marketing and <font color="blue">distribution</font> experience with our Piccolo systems in the human     <font color="blue"><font color="blue">diagnostic</font> market</font></td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">cannot assure</font> you that:                                         •          we will be able to establish and maintain <font color="blue">effective</font> <font color="blue">distribution</font>                  <font color="blue">arrangements</font> in the <font color="blue">human <font color="blue"><font color="blue">diagnostic</font> market</font></font>;                                             •        any <font color="blue">distribution</font> <font color="blue">arrangements</font> that we are able to <font color="blue">establish will</font> be                    successful in marketing our products; or                                             •     the <font color="blue">costs associated with marketing</font> and <font color="blue">distributing</font> our <font color="blue">products will</font> not                                 be excessive</td>
    </tr>
    <tr>
      <td>Should  we  fail  to <font color="blue"><font color="blue">effective</font>ly</font> develop our marketing and     <font color="blue">distribution</font>  efforts,  our  <font color="blue">growth will</font> be limited and our results of     <font color="blue">operations</font> will be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We May Inadvertently Produce Defective Products, Which May Subject Us to     Significant Warranty Liabilities Or Product Liability Claims And We May Have     Insufficient Product Liability Insurance                 Our  business  exposes  us to <font color="blue">potential warranty</font> and product     <font color="blue">liability</font>  risks  which are inherent in the testing, <font color="blue">manufacturing</font> and     marketing of human and <font color="blue"><font color="blue">veterinary</font> medical products</font></td>
    </tr>
    <tr>
      <td>We strive to apply     <font color="blue">sophisticated methods</font> to <font color="blue">raw materials</font> and produce defect-free medical test     equipment</td>
    </tr>
    <tr>
      <td>Although we have <font color="blue">established procedures</font> for <font color="blue">quality control on</font>     both the <font color="blue">raw materials</font> that we receive <font color="blue">from suppliers</font> and our <font color="blue"><font color="blue">manufacture</font>d</font>     <font color="blue">final products</font>, these <font color="blue">procedures may prove</font> inadequate to detect a defect     that either occurs in limited quantities or that we have not anticipated</td>
    </tr>
    <tr>
      <td>We believe that our <font color="blue">Piccolo and VetScan </font>systems detect the vast majority of     errors that occur on our <font color="blue"><font color="blue">reagent disc</font>s</font> and <font color="blue">automatically reject such tests</font>,     prompting the <font color="blue">medical provider</font> to retest the patient</td>
    </tr>
    <tr>
      <td>However, our <font color="blue">Piccolo  </font>   and VetScan <font color="blue">systems may</font> be unable to detect <font color="blue">errors which could</font> result in the     <font color="blue">misdiagnosis</font> of human or <font color="blue"><font color="blue">veterinary</font> patients</font></td>
    </tr>
    <tr>
      <td>Should we <font color="blue">inadvertently ship</font> defective products, we may be subject     to substantial claims under our <font color="blue">warranty policy</font> or product <font color="blue">liability</font> law</td>
    </tr>
    <tr>
      <td>In addition, our policy is to credit <font color="blue">medical provider</font>s for any defective     product that we produce, including those <font color="blue"><font color="blue">reagent disc</font>s</font> that are <font color="blue">rejected by</font>     our <font color="blue">Piccolo and VetScan </font>systems</td>
    </tr>
    <tr>
      <td>Therefore, even if a <font color="blue">mass defect within</font> a     lot  or lots of <font color="blue"><font color="blue">reagent disc</font>s</font> were detected by our <font color="blue">Piccolo and VetScan </font>    systems,  our  need to replace such <font color="blue"><font color="blue">reagent disc</font>s</font> free of <font color="blue">charge would</font>     <font color="blue">materially</font> harm our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Further, in the event that a     <font color="blue">product defect</font> is not detected by our Piccolo system, our <font color="blue">relatively</font> recent     <font color="blue">expansion into</font> the <font color="blue">human <font color="blue">medical market</font></font> greatly increases the risk that the     amount of damages involved with just one <font color="blue">product defect</font> would be material to     our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We currently maintain limited product <font color="blue">liability</font> insurance     that we believe is adequate for our needs, taking <font color="blue">into account</font> the risks     involved and cost of coverage</td>
    </tr>
    <tr>
      <td>However, our product <font color="blue">liability</font> insurance and     cash may be insufficient to <font color="blue">cover potential liabilities</font></td>
    </tr>
    <tr>
      <td>In addition, in     the future the coverage that we require may be <font color="blue">unavailable on commercially</font>     <font color="blue">reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>Even with our <font color="blue">current insurance coverage</font>, a     mass <font color="blue">product defect</font>, product <font color="blue">liability</font> claim or recall would <font color="blue">materially</font>     <font color="blue">adversely</font> affect our business or our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Many of Our Sales Force Have Been Employed By Us For Less Than One Year And     We Must Effectively Train And Integrate Our Sales Team In Order To Achieve     Our Anticipated Revenue                 At March 31, 2006, we had fifty-two full-time sales personnel     involved in our sales and marketing <font color="blue">activities</font>, many of whom have been     <font color="blue">employed by us</font> for a limited period of time</td>
    </tr>
    <tr>
      <td>While these <font color="blue">individuals</font> work     with our <font color="blue">distribution</font> partners both domestically and <font color="blue"><font color="blue">international</font>ly</font> to     extend our <font color="blue">market reach</font>, the primary selling <font color="blue">activities</font> are <font color="blue">often done by</font>     these <font color="blue">individuals</font></td>
    </tr>
    <tr>
      <td>If we are to increase our sales, we will need to train     <font color="blue">new salespeople</font> and <font color="blue">supervise them closely</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also <font color="blue">will continue</font> hiring</font>     <font color="blue">additional</font>  sales  personnel</td>
    </tr>
    <tr>
      <td>If we are unable to retain our existing     personnel, or attract and train <font color="blue">additional</font> qualified personnel, our growth     may be limited due to our lack of resources to market our products</td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________       We Need to Successfully Manufacture And Market Additional Reagent Discs For     The Human Diagnostic Market If We Are To Compete In That Market                 We have developed a <font color="blue">blood analysis system</font> that consists of a     <font color="blue">portable blood analyzer</font> and single-use <font color="blue"><font color="blue">reagent disc</font>s</font></td>
    </tr>
    <tr>
      <td>Each <font color="blue">reagent disc</font>     performs a series of standard <font color="blue">blood tests</font></td>
    </tr>
    <tr>
      <td>We believe that it is <font color="blue">necessary</font>     to develop <font color="blue">additional</font> series of <font color="blue"><font color="blue">reagent disc</font>s</font> with various tests for use     with the <font color="blue">Piccolo and VetScan </font>systems</td>
    </tr>
    <tr>
      <td>Historically, we primarily developed     <font color="blue"><font color="blue">reagent disc</font>s</font> suitable for the <font color="blue"><font color="blue">veterinary</font> <font color="blue"><font color="blue">diagnostic</font> market</font></font></td>
    </tr>
    <tr>
      <td>These tests are included in standard tests for     which the <font color="blue">medical community</font> receives <font color="blue"><font color="blue">reimbursement</font>s from <font color="blue">third party</font> payors</font>     such as <font color="blue">HMOs and Medicare</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully <font color="blue">manufacture</font></font>     or market these <font color="blue"><font color="blue">reagent disc</font>s</font></td>
    </tr>
    <tr>
      <td>Our failure to meet these <font color="blue">challenges will</font>     <font color="blue">materially</font> <font color="blue">adversely</font> affect our operating results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We Rely On Distributors To Sell Our Products; We Rely On Sole Distributor     Arrangements In A Number Of Countries                 We sell our products primarily through <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td>As a result,     we are <font color="blue">dependent</font> upon these <font color="blue"><font color="blue">distributor</font>s</font> to sell our products and to assist     us in promoting and creating a demand for our products</td>
    </tr>
    <tr>
      <td>We operate on a     purchase order <font color="blue">basis with</font> the <font color="blue"><font color="blue">distributor</font>s</font> and the <font color="blue"><font color="blue">distributor</font>s</font> are under no     <font color="blue">contractual obligation</font> to continue carrying our products</td>
    </tr>
    <tr>
      <td>Further, many of     our <font color="blue"><font color="blue">distributor</font>s</font> may carry our <font color="blue">competitors</font>’ products, and <font color="blue">may promote</font> our     <font color="blue">competitors</font>’ products over our own products</td>
    </tr>
    <tr>
      <td>Two <font color="blue"><font color="blue">distributor</font>s</font>, <font color="blue">Henry Schein </font>    and DVM Resources accounted for 17prca and 13prca, respectively, of <font color="blue">total revenues</font>     for fiscal 2006</td>
    </tr>
    <tr>
      <td>Two <font color="blue"><font color="blue">distributor</font>s</font>, DVM Resources and Vedco, Inc, accounted     for 17prca and 14prca of <font color="blue">total revenues</font> for fiscal 2005</td>
    </tr>
    <tr>
      <td>We  have  a  number of <font color="blue"><font color="blue">distributor</font>s</font> in the <font color="blue"><font color="blue">United States</font> </font>who     distribute  our  VetScan  products</td>
    </tr>
    <tr>
      <td>While we continue to <font color="blue">enter into</font>     <font color="blue">arrangements</font> with <font color="blue">veterinary</font> <font color="blue"><font color="blue">distributor</font>s</font>, we have <font color="blue">also terminated</font> our     <font color="blue">distribution</font> <font color="blue">relationships</font> with the <font color="blue">veterinary</font> division of <font color="blue">Henry Schein </font>in     May 2006 and Vedco, Inc</td>
    </tr>
    <tr>
      <td>in <font color="blue">December </font>2004</td>
    </tr>
    <tr>
      <td>While we have in the past, and     expect  to  in the future, support those customers who were <font color="blue">previously</font>     supplied  <font color="blue">products by</font> <font color="blue">Henry Schein </font>and Vedco, Inc</td>
    </tr>
    <tr>
      <td>through our current     <font color="blue"><font color="blue">distributor</font> base</font> and <font color="blue">direct service</font>, the loss of these or other <font color="blue"><font color="blue">distributor</font>s</font>     <font color="blue">may negatively affect</font> our <font color="blue">future revenues</font></td>
    </tr>
    <tr>
      <td>Accordingly, if one or more of     our <font color="blue"><font color="blue">distributor</font>s</font> were to stop selling our products in the future, we may not     be able to <font color="blue">replace such lost revenue</font> or experience a delay in our sales     revenue</td>
    </tr>
    <tr>
      <td>In the <font color="blue"><font color="blue">United States</font> </font><font color="blue">medical market</font>, we <font color="blue">entered into</font> a formal     <font color="blue">distribution</font> agreement with PSS World Medical, Inc</td>
    </tr>
    <tr>
      <td>in the <font color="blue">third quarter</font> of     fiscal 2006, to sell and market Piccolo systems and the <font color="blue">medical reagent</font>     discs</td>
    </tr>
    <tr>
      <td>Internationally, we have a few <font color="blue"><font color="blue">distributor</font>s</font> for our products in both     the human and <font color="blue"><font color="blue">veterinary</font> <font color="blue"><font color="blue">diagnostic</font> market</font></font>s, which includes <font color="blue">one <font color="blue">distributor</font></font>     in  Japan  who  received clearance <font color="blue">in <font color="blue">September </font></font>2005 from the <font color="blue">Japanese     </font><font color="blue"><font color="blue">regulatory</font> agency</font> to import and market our complete line of <font color="blue">medical reagent</font>     discs, the Piccolo system, as well as all <font color="blue">veterinary</font> <font color="blue"><font color="blue">reagent disc</font>s</font> and the     Vetscan DXS system, with the exception of those <font color="blue">products containing</font> the Bile     Acid assay in the <font color="blue">respective country</font></td>
    </tr>
    <tr>
      <td>We currently have <font color="blue"><font color="blue">distributor</font>s</font> for our products in the following     countries:  Australia, Austria, Bahrain, Belgium, Canada, Denmark, France,     Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Kuwait, Macao,     Mexico, the Netherlands, New Zealand, Norway, Portugal, Russia, Singapore,     South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, the     <font color="blue">United Kingdom and the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">distributor</font> in each of these     countries is responsible for obtaining the <font color="blue">necessary</font> approvals to sell our     products</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">distributor</font>s</font> may not be successful in obtaining proper     approvals for our products in their <font color="blue">respective countries</font>, and they may not     be successful in marketing our products</td>
    </tr>
    <tr>
      <td>We plan to continue to <font color="blue">enter into</font>     <font color="blue">additional</font>  <font color="blue">distributor</font>  <font color="blue">relationships</font>  to  expand  our  <font color="blue">international</font>     <font color="blue">distribution</font> base and solidify our <font color="blue">international</font> presence</td>
    </tr>
    <tr>
      <td>However, we may     not be successful in entering into <font color="blue">additional</font> <font color="blue">distributor</font> <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">distributor</font>s</font> may terminate their <font color="blue">relationship with us at</font> any time</td>
    </tr>
    <tr>
      <td>Historically,  we  have experienced a <font color="blue">turnover among</font> our <font color="blue">international</font>     <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td>This high degree of turnover makes it <font color="blue">difficult</font> for us to     establish a steady <font color="blue">distribution</font> network overseas</td>
    </tr>
    <tr>
      <td>Consequently, we may not     be  successful  in  marketing  our  <font color="blue">Piccolo  </font>and  VetScan DXS products     <font color="blue"><font color="blue">international</font>ly</font></td>
    </tr>
    <tr>
      <td>We Depend On Sole Suppliers For Several Key Components In Our Products, Many     of Whom We Have Not Entered Into Contractual Relationships With                  We <font color="blue">use several key components</font> that are <font color="blue">currently available from</font>     limited or <font color="blue">sole sources as discussed</font> below:                                         •      Reagent Discs:  Two injection molding <font color="blue"><font color="blue">manufacture</font>r</font>s, C Brewer &amp; Co</td>
    </tr>
    <tr>
      <td>and     Nypro Oregon, Inc, currently make the <font color="blue"><font color="blue"><font color="blue">molded plastic</font> discs</font> which</font>, when    <font color="blue">loaded with reagents</font> and <font color="blue">welded together</font>, form our <font color="blue"><font color="blue">reagent disc</font> products</font></td>
    </tr>
    <tr>
      <td>We believe that only a few <font color="blue"><font color="blue">manufacture</font>r</font>s are capable of producing these     discs to the narrow tolerances that we require</td>
    </tr>
    <tr>
      <td>To date, we have only   qualified these two <font color="blue"><font color="blue">manufacture</font>r</font>s, with Nypro Oregon, Inc</td>
    </tr>
    <tr>
      <td>being qualified      <font color="blue">at two separate <font color="blue">facilities</font></font>, to <font color="blue">manufacture</font> the <font color="blue"><font color="blue">molded plastic</font> discs</font></td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________                                         •       Reagent Chemicals:  We <font color="blue">currently depend on</font> the <font color="blue">following single source</font>    vendors for some of the <font color="blue">chemicals</font> that we use to produce the dry reagent   <font color="blue">chemistry</font> beads that are <font color="blue">either inserted</font> in our <font color="blue"><font color="blue">reagent disc</font>s</font> or sold as a     stand-alone product:  Amano Enzyme USA Co, Ltd, Genzyme Corporation,    Kikkoman <font color="blue">Corporation </font>Biochemical Division, Microgenics Corporation, Roche    Molecular Bio<font color="blue">chemicals</font> of Roche Diagnostics Corporation, a division of F      Hoffmann-La Roche, Ltd, Shinko American Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">Sigma Aldrich Inc</font></td>
    </tr>
    <tr>
      <td>•           Blood Analyzer Components:  Our <font color="blue">analyzer products use several</font>     <font color="blue">technologically advanced components</font> that we <font color="blue">currently purchase from</font> the   <font color="blue">following single source</font> vendors, Electro Alliance, Inc, PerkinElmer, Inc,    and UDT Sensors</td>
    </tr>
    <tr>
      <td>Our <font color="blue">analyzers</font> use a printer that is only made by Seiko       North America Corporation</td>
    </tr>
    <tr>
      <td>The loss of the supply of any of these              <font color="blue">components could force us</font> to redesign our <font color="blue">analyzers</font></td>
    </tr>
    <tr>
      <td>•      Hematology Instruments and Reagents:  The VetScan HMII is <font color="blue"><font color="blue">manufacture</font>d</font> by    <font color="blue">Diatron in Hungary </font>and is <font color="blue">purchased by</font> us as a completed instrument</td>
    </tr>
    <tr>
      <td>To     date, we have <font color="blue">qualified two suppliers</font> to produce the reagents for the        <font color="blue">hematology instruments</font>:  Clinical Diagnostic Solutions, Inc</td>
    </tr>
    <tr>
      <td>and                             Mallinckrodt Baker BV                  For our <font color="blue">hematology instruments</font> purchased from Diatron, we are     subject to minimum purchase <font color="blue"><font color="blue">requirements</font> through</font> fiscal 2009</td>
    </tr>
    <tr>
      <td>We operate on     a purchase order <font color="blue">basis with</font> all of the suppliers of our <font color="blue">molded plastic</font>     <font color="blue"><font color="blue">reagent disc</font>s</font>, reagent <font color="blue">chemicals</font> and <font color="blue">blood analyzer components</font> and thus     these suppliers are under no <font color="blue">contractual obligation</font> to <font color="blue">supply us with</font> their     products or to do so <font color="blue">at specified prices</font></td>
    </tr>
    <tr>
      <td>Although we believe that there     are <font color="blue">potential alternate suppliers available</font> for these <font color="blue">critical components</font>,     to date we have not qualified <font color="blue">additional</font> vendors beyond those referenced     above</td>
    </tr>
    <tr>
      <td>Because we are <font color="blue">dependent</font> on a limited number of suppliers and     <font color="blue"><font color="blue">manufacture</font>r</font>s for <font color="blue">critical components</font> to our products, we are <font color="blue">particularly</font>     susceptible to any <font color="blue">interruption</font> in the supply of these products or the     viability  of our assembly <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>The loss of any one of these     suppliers or a <font color="blue">disruption</font> in our <font color="blue">manufacturing</font> <font color="blue">arrangements</font> could <font color="blue">materially</font>     <font color="blue">adversely</font> affect our business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We Compete With Larger, Better Established Entities Such As Hospitals And     Commercial Laboratories                  Blood analysis is a well established field in <font color="blue">which there</font> are a     number of <font color="blue">competitors</font> that have <font color="blue">substantially greater financial resources</font>     and larger, more established marketing, sales and <font color="blue">service organizations than</font>     we do</td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font> the <font color="blue">following organizations</font>:                                         •                         commercial <font color="blue">clinical <font color="blue">laboratories</font></font>;                                             •                       hospitals’ <font color="blue">clinical <font color="blue">laboratories</font></font>; and                                             •       <font color="blue"><font color="blue">manufacture</font>r</font>s of bench top multi-test blood <font color="blue">analyzers</font> and other testing             systems that health <font color="blue">care providers</font> can use “on-site</td>
    </tr>
    <tr>
      <td>”       We May Not Be Able To Compete With Larger, Better Established Entities Or     Their Products Or With Future Organizations Or Future Products                  Historically, hospitals and <font color="blue">commercial <font color="blue">laboratories</font></font> performed     <font color="blue">most human <font color="blue">diagnostic</font> testing</font>, and <font color="blue">commercial <font color="blue">laboratories</font></font> performed the     most <font color="blue">veterinary</font> medical testing</td>
    </tr>
    <tr>
      <td>We have identified <font color="blue">five principal factors</font>     that <font color="blue">customers typically use</font> to evaluate our products and those of our     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>These factors are:                                         •                              range of <font color="blue">tests offered</font>;                                             •                             the immediacy of results;                                             •                                <font color="blue">cost <font color="blue">effective</font>ness</font>;                                             •                                  ease of use; and                                             •                              re<font color="blue">liability</font> of results</td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________                 We believe that we compete <font color="blue"><font color="blue">effective</font>ly</font> on each of these factors     except for the range of <font color="blue">tests offered</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">laboratories</font> are <font color="blue">effective</font>     <font color="blue">at processing</font> large panels of <font color="blue">tests using skilled technicians</font> and complex     equipment</td>
    </tr>
    <tr>
      <td>While our <font color="blue">current offering</font> of <font color="blue"><font color="blue">reagent disc</font>s</font> cannot provide the     <font color="blue">same broad range</font> of tests, we believe that in <font color="blue">certain markets</font> our products     provide a <font color="blue">sufficient breadth</font> of test menus to <font color="blue">compete successfully with</font>     <font color="blue">clinical <font color="blue">laboratories</font></font> given the <font color="blue">advantages</font> of our <font color="blue">products with respect</font> to     the other <font color="blue">four factors</font></td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot assure</font> you that we <font color="blue">will continue</font>     to  be able to compete <font color="blue"><font color="blue">effective</font>ly</font> on <font color="blue">cost <font color="blue">effective</font>ness</font>, ease of use,     immediacy of results or re<font color="blue">liability</font> of results</td>
    </tr>
    <tr>
      <td>We also <font color="blue">cannot assure</font> you     that we will ever be able to compete <font color="blue"><font color="blue">effective</font>ly</font> on the basis of range of     <font color="blue">tests offered</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in the human and <font color="blue"><font color="blue">veterinary</font> <font color="blue"><font color="blue">diagnostic</font> market</font></font>s is     intense</td>
    </tr>
    <tr>
      <td>Our principal <font color="blue">competitors</font> in the <font color="blue">human <font color="blue"><font color="blue">diagnostic</font> market</font></font> are Alfa     Wassermann  SPA,  i-STAT <font color="blue">Corporation </font>(which was <font color="blue">purchased by</font> Abbott     Laboratories), Johnson &amp; Johnson (including its subsidiary, Ortho-Clinical     Diagnostics,  Inc</td>
    </tr>
    <tr>
      <td>Our principal <font color="blue">competitors</font> in the     <font color="blue">veterinary</font>  <font color="blue">diagnostic</font>  market  are Idexx Laboratories, Inc</td>
    </tr>
    <tr>
      <td>Most of our <font color="blue">competitors</font> have <font color="blue">significantly</font> greater financial     and other <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>In particular, many of our <font color="blue">competitors</font> have     large   sales   forces  and  well-established  <font color="blue">distribution</font>  channels</td>
    </tr>
    <tr>
      <td>Consequently, we must develop our <font color="blue"><font color="blue">distribution</font> channels</font> and improve our     <font color="blue">direct sales force</font> in order to compete in these markets</td>
    </tr>
    <tr>
      <td>Changes In Third Party Payor Reimbursement Regulations Can Negatively Affect     Our Business                 By  regulating the <font color="blue">maximum amount</font> of <font color="blue">reimbursement</font> they will     provide  for <font color="blue">blood <font color="blue">testing services</font></font>, <font color="blue">third party</font> payors, such as HMOs,     pay-per-service insurance plans, Medicare and Medicaid, can <font color="blue">indirectly</font>     affect the pricing or the <font color="blue">relative attractiveness</font> of our <font color="blue">human testing</font>     products</td>
    </tr>
    <tr>
      <td>For example, the Centers for <font color="blue">Medicare and Medicaid </font>Services (CMS)     sets the level of <font color="blue">reimbursement</font> of fees for <font color="blue">blood <font color="blue">testing services</font></font> for     Medicare <font color="blue">beneficiaries</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">third party</font> payors decrease</font> the <font color="blue">reimbursement</font>     amounts  for  blood  <font color="blue">testing services</font>, it may decrease the amount that     physicians and hospitals are able to <font color="blue">charge patients</font> for <font color="blue">such services</font></td>
    </tr>
    <tr>
      <td>Consequently,  we  will  need to <font color="blue">charge less</font> for our products</td>
    </tr>
    <tr>
      <td>If the     <font color="blue">government</font> and <font color="blue">third party</font> payors do not provide for adequate coverage and     <font color="blue">reimbursement</font> levels to allow health <font color="blue">care providers</font> to use our products, the     demand for our <font color="blue">products will</font> decrease</td>
    </tr>
    <tr>
      <td>We Are Subject To Numerous Governmental Regulations                                         •             Need for FDA Certification for Our Medical Device Products                  Our Piccolo products are <font color="blue">regulated under</font> the 1976 Medical Device     Amendments to the Food, Drug and Cosmetic Act, which is <font color="blue">administered by</font> the     <font color="blue">Food and Drug Administration </font>(FDA)</td>
    </tr>
    <tr>
      <td>The FDA has classified our <font color="blue">Piccolo  </font>   <font color="blue">products as</font> “Class I” and “Class II” devices</td>
    </tr>
    <tr>
      <td>These <font color="blue">classifications</font> require     us to submit to the FDA a pre-market <font color="blue">notification</font> form or 510(k)</td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font>uses the 510(k) to <font color="blue">substantiate product</font> claims that are made by medical     device <font color="blue"><font color="blue">manufacture</font>r</font>s prior to marketing</td>
    </tr>
    <tr>
      <td>In our 510(k) <font color="blue">notification</font>, we     must, among other things, establish that the product we plan to market is     “<font color="blue">substantially equivalent</font>” to (1) a product that was on the <font color="blue">market prior</font> to     the adoption of the 1976 <font color="blue">Medical Device Amendment </font>or (2) to a product that     the FDA has <font color="blue">previously</font> cleared under the 510(k) process</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">review process</font> of a 510(k) <font color="blue">notification</font> can <font color="blue">last anywhere</font>     from three to six months, and the FDA must issue a written order finding     “substantial equivalence” before a company can market a medical device</td>
    </tr>
    <tr>
      <td>As     of March 31, 2006, we have received <font color="blue">market clearance from</font> the FDA for our     Piccolo system and 25 reagent tests that we have on 12 <font color="blue"><font color="blue">reagent disc</font>s</font></td>
    </tr>
    <tr>
      <td>We     are currently developing <font color="blue">additional</font> tests that the FDA will have to clear     through the 510(k) <font color="blue">notification</font> procedures</td>
    </tr>
    <tr>
      <td>These <font color="blue">new test products</font> are     crucial for our success in the <font color="blue">human <font color="blue">medical market</font></font></td>
    </tr>
    <tr>
      <td>If we do not receive     510(k) clearance for a <font color="blue">particular product</font>, we will not be able to sell that     product in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>•                   <font color="blue">Need to Comply </font>with Manufacturing Regulations                  The 1976 <font color="blue">Medical Device Amendment </font>also requires us to <font color="blue">manufacture</font>     our  <font color="blue">Piccolo  </font>products in <font color="blue">accordance with</font> <font color="blue"><font color="blue">Good Manufacturing Practices </font>    </font><font color="blue">guidelines</font></td>
    </tr>
    <tr>
      <td><font color="blue">Current Good Manufacturing Practice </font><font color="blue">requirements</font> are set forth     in the 21 CFR 820 <font color="blue"><font color="blue">Quality System </font>Regulation</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">requirements</font> regulate     the <font color="blue">methods used</font> in, and the <font color="blue">facilities</font> and <font color="blue">controls used</font> for the design,     <font color="blue">manufacture</font>, packaging, storage, installation and servicing of our medical     <font color="blue">devices intended</font> for human use</td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> <font color="blue">facility</font> is subject to     <font color="blue">periodic inspections</font></td>
    </tr>
    <tr>
      <td>Although we have obtained a <font color="blue">license from</font> the State of     <font color="blue">California </font>to <font color="blue">manufacture</font> our products, various state <font color="blue">regulatory</font> agencies     may regulate the <font color="blue">manufacture</font> of our products</td>
    </tr>
    <tr>
      <td>To date, we have complied     with the following:                                         •       In April 2001, the State of <font color="blue">California </font>Food and Drug Branch granted our   <font color="blue">manufacturing</font> <font color="blue">facility</font> “in compliance” status, based on the <font color="blue">regulations</font> for               <font color="blue">Good Manufacturing Practices </font>for <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>•     In May 2001, the State of <font color="blue">California </font>Food and Drug Branch <font color="blue">granted licensing</font>           for our <font color="blue">manufacturing</font> <font color="blue">facility</font> in Union City, California</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________                                         •         In May 2002, we received our ISO 9001 <font color="blue">certification</font>, expanding our                <font color="blue">compliance with</font> <font color="blue">international</font> quality standards</td>
    </tr>
    <tr>
      <td>•       In <font color="blue">December </font>2003, we received ISO 13485 <font color="blue">Quality System </font><font color="blue"><font color="blue">certification</font> as</font>  required by the 2003 <font color="blue">European In Vitro Device Directive</font></td>
    </tr>
    <tr>
      <td>This certified our                <font color="blue">quality system specifically</font> to <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>•      In both <font color="blue">September </font>2005 and March 2003, the US FDA conducted a <font color="blue">facility</font>     inspection and verified our <font color="blue">compliance with</font> the 21 CFR 820 Regulation</td>
    </tr>
    <tr>
      <td>We  cannot  assure  you  that  we <font color="blue"><font color="blue">will successfully</font> pass</font> a     re-inspection by the <font color="blue">US FDA or the State of California</font></td>
    </tr>
    <tr>
      <td>In addition, we     <font color="blue">cannot assure</font> you that we can <font color="blue">comply with</font> all current or future <font color="blue">government</font>     <font color="blue">manufacturing</font> <font color="blue">requirements</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">comply with</font>     the <font color="blue">regulations</font>, or if we do not <font color="blue">pass routine inspections</font>, our business and     results of <font color="blue">operations</font> will be <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>•      Effects of the Clinical Laboratory Improvement Amendments on Our Products                  Our Piccolo products are <font color="blue">affected by</font> the Clinical Laboratory     Improvement Amendments (CLIA) of 1988</td>
    </tr>
    <tr>
      <td>The Clinical Laboratory Improvement     Amendments (CLIA) are intended to insure the quality and re<font color="blue">liability</font> of all     medical  testing  in  the  <font color="blue"><font color="blue">United States</font> </font><font color="blue">regardless</font> of where tests are     performed</td>
    </tr>
    <tr>
      <td>The current Clinical Laboratory Improvement Amendments (CLIA)     divide  <font color="blue"><font color="blue">laboratory</font> tests into three categories</font>:  “simple,” “moderately     complex” and “<font color="blue">highly complex</font></td>
    </tr>
    <tr>
      <td>”  Tests performed using the Piccolo system are     in the “<font color="blue">moderately complex</font>” category</td>
    </tr>
    <tr>
      <td>This category requires that any     location in <font color="blue">which testing</font> is performed be <font color="blue">certified as</font> a <font color="blue">laboratory</font></td>
    </tr>
    <tr>
      <td>Hence,     we can only sell our Piccolo products to customers who meet the standards of     a <font color="blue">laboratory</font></td>
    </tr>
    <tr>
      <td>To receive “<font color="blue">laboratory</font>” <font color="blue">certification</font>, a testing <font color="blue">facility</font>     must be <font color="blue">certified by</font> the Centers for <font color="blue">Medicare and Medicaid </font>Services (CMS)</td>
    </tr>
    <tr>
      <td>After the testing <font color="blue">facility</font> receives a “<font color="blue">laboratory</font>” <font color="blue">certification</font>, it must     then  meet  the  Clinical  Laboratory  Improvement  Amendments  (CLIA)     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Because we can only sell our Piccolo products to testing     <font color="blue">facilities</font> that are certified “<font color="blue">laboratories</font>,” the market for our products is     <font color="blue">correspondingly constrained</font></td>
    </tr>
    <tr>
      <td>The tests included on our <font color="blue">Lipid Panel and Lipid Panel Plus     </font><font color="blue"><font color="blue">reagent disc</font>s</font> have <font color="blue">been granted <font color="blue">waived status</font> under</font> CLIA <font color="blue">regulations</font> for our     <font color="blue">total cholesterol</font>, HDL, triglycerides, glucose, <font color="blue">ALT and AST </font>tests when used     in <font color="blue">conjunction with</font> our Piccolo system</td>
    </tr>
    <tr>
      <td>Waived <font color="blue">status permits untrained</font>     personnel to run the Piccolo system using the Lipid Panel and Lipid Panel     Plus; thus, extending the sites (doctors’ offices and other point-of-care     <font color="blue">environments</font>) that can use the Piccolo system</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we <font color="blue">will successfully</font> receive the waived     <font color="blue">status from</font> the FDA for other products</td>
    </tr>
    <tr>
      <td>Consequently, for the <font color="blue"><font color="blue">reagent disc</font>s</font>     that  have not received CLIA <font color="blue">waived status</font>, the market for our <font color="blue">Piccolo  </font>   <font color="blue">products may</font> be confined to those testing <font color="blue">facilities</font> that are <font color="blue">certified as</font>     “<font color="blue">laboratories</font>” and our growth can be limited <font color="blue">according</font>ly</td>
    </tr>
    <tr>
      <td>However, we are     engaged  in  an  active  program to test and apply for CLIA waiver for     <font color="blue">additional</font> analytes</td>
    </tr>
    <tr>
      <td>•         We Are Subject to Various Federal, State, Local, and International                                  Regulations                  Federal, state, local and <font color="blue">international</font> <font color="blue">regulations</font> regarding the     <font color="blue">manufacture</font> and sale of <font color="blue">health care products</font> and <font color="blue">diagnostic</font> devices may     change</td>
    </tr>
    <tr>
      <td>In addition, as we continue to sell in <font color="blue">foreign markets</font>, we may have     to obtain <font color="blue">additional</font> <font color="blue">government</font>al clearances in those markets</td>
    </tr>
    <tr>
      <td>We have     received the following <font color="blue">certification</font>s:                                         •       In <font color="blue">December </font>2003, we received <font color="blue">certification</font> from the British Standards      Institute to the ISO 13485:1996 quality system standard for medical       devices</td>
    </tr>
    <tr>
      <td>This quality system <font color="blue">certification</font>, along with successful  <font color="blue">completion</font> of <font color="blue">product testing</font> to 2003 European standards and the <font color="blue">translation</font>   of Piccolo <font color="blue">product documentation into</font> the required languages, enabled us to    meet the compliance <font color="blue">requirements</font> of the CE Mark and the 2003 European In                            Vitro Device Directive</td>
    </tr>
    <tr>
      <td>•       In <font color="blue">September </font>2005, we received the Canadian Medical Device Conformity    Assessment System (CMDCAS) stamp on our ISO 13485 certificate to signify                   <font color="blue">compliance with</font> <font color="blue">Health Canada </font><font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>•     In March 2006, we received our <font color="blue">certification</font> to the 2003 version of the <font color="blue">ISO               </font>13485 quality system standard for <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> what impact, if any, <font color="blue">such current</font> or future     <font color="blue">regulatory</font> changes would have on our business</td>
    </tr>
    <tr>
      <td>We may not be able to obtain     <font color="blue">regulatory</font> clearances for our products in the <font color="blue"><font color="blue">United States</font> </font>or in foreign     markets,  and  the  failure to obtain these <font color="blue">regulatory</font> clearances will     <font color="blue">materially</font> <font color="blue">adversely</font> affect our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Although we believe that we will be able to <font color="blue">comply with</font> all     applicable <font color="blue">regulations</font> of the <font color="blue">Food and Drug Administration </font>and of the State     of California, including the <font color="blue"><font color="blue">Quality System </font>Regulation</font>, current <font color="blue">regulations</font>     <font color="blue">depend on administrative <font color="blue">interpretations</font></font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">interpretations</font> made by     the Food and Drug Administration, the Centers for <font color="blue">Medicare and Medicaid </font>    Services (CMS) or other <font color="blue">regulatory</font> bodies may <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       We Depend On Key Members Of Our Management And Scientific Staff, And We Must     Retain And Recruit Qualified Individuals If We Are To Be Competitive                 We are highly <font color="blue">dependent</font> on the <font color="blue">principal members</font> of our <font color="blue">management</font>     and <font color="blue">scientific staff</font></td>
    </tr>
    <tr>
      <td>The loss of any of these <font color="blue">key personnel</font>, including in     particular Clinton H Severson, our President, Chief Executive Officer and     <font color="blue">Chairman </font>of our Board of Directors, <font color="blue">might impede</font> the <font color="blue">achievement</font> of our     business  <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>Severson’s amended and <font color="blue">restated employment</font>     <font color="blue">agreement with us</font> has <font color="blue">been filed with</font> the <font color="blue"><font color="blue">Securities and <font color="blue">Exchange Commission </font></font>    </font>as an exhibit</td>
    </tr>
    <tr>
      <td>We currently do not maintain <font color="blue">key man life insurance on</font> any     of our employees</td>
    </tr>
    <tr>
      <td>Although <font color="blue">historically</font> we have been <font color="blue">relatively</font> successful     both in retaining our current <font color="blue">management</font> and <font color="blue">scientific staff</font>, as well as     attracting  and retaining skilled and experienced marketing, sales and     <font color="blue">manufacturing</font> personnel, we may not be able to <font color="blue">employ such personnel on</font>     acceptable terms in the future because <font color="blue">numerous medical products</font> and other     high  <font color="blue">technology companies compete</font> for the services of these qualified     <font color="blue">individuals</font></td>
    </tr>
    <tr>
      <td><font color="blue">Standards For Compliance With Section </font>404 Of the Sarbanes-Oxley Act Of 2002     Are Complex, And If We Are Unable To Maintain Effective Internal Control     Over Our Financial Reporting, Our Business Could Be Harmed And Our Stock     Price Could Decline                 Rules <font color="blue">adopted by</font> the <font color="blue">Securities and <font color="blue">Exchange Commission </font></font>pursuant     to  <font color="blue">Section  </font>404  of  the Sarbanes-Oxley Act of 2002 require an annual     <font color="blue">assessment</font>  of  internal  control  over financial reporting by Abaxis’     <font color="blue">management</font> and an <font color="blue">attestation</font> of its <font color="blue">assessment</font> by in<font color="blue">dependent</font> registered     <font color="blue">public accountants</font></td>
    </tr>
    <tr>
      <td>The standards that must be met for <font color="blue">management</font> to assess     the <font color="blue">internal <font color="blue">control over financial</font></font> reporting as <font color="blue">effective</font> are new and     complex, require significant documentation, testing and <font color="blue">possible remediation</font>     to meet the <font color="blue">detailed standards</font></td>
    </tr>
    <tr>
      <td>Abaxis’ <font color="blue">management</font> assessed the <font color="blue">effective</font>ness of its internal     <font color="blue">control over financial</font> reporting as of March 31, 2006 and March 31, 2005</td>
    </tr>
    <tr>
      <td>The  <font color="blue">assessment</font>  for fiscal 2005 identified a material weakness in its     <font color="blue">internal <font color="blue">control over financial</font></font> reporting related to in<font color="blue">effective</font> controls     over the <font color="blue">determination</font> and reporting of the provision for <font color="blue">income taxes</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">control deficiency</font> identified in fiscal 2005 could have resulted in a future     material <font color="blue">misstatement</font> of the Company’s <font color="blue">income tax provision</font> (and related     <font color="blue">balance sheet accounts</font>) that would not have <font color="blue">been prevented</font> or detected by     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Although  Abaxis  received an <font color="blue">unqualified opinion on</font> its     <font color="blue">financial statements</font> for the <font color="blue">fiscal year</font> ended March 31, 2006, and on the     <font color="blue">effective</font>ness of its <font color="blue">internal <font color="blue">control over financial</font></font> reporting, the steps     Abaxis has taken to date and the steps Abaxis is still in the process of     taking to improve the re<font color="blue">liability</font> of its <font color="blue">financial statements</font> in the future     are subject to continued <font color="blue">management</font> review, as well as oversight by the     audit  committee  of its board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Any failure to implement     required  new  or  improved  controls,  or <font color="blue">difficult</font>ies encountered in     <font color="blue">implementation</font> could harm operating results or prevent the Company from     <font color="blue">accurately</font> reporting financial results or cause a <font color="blue">failure by</font> Abaxis to meet     its reporting <font color="blue">obligations</font> in the future</td>
    </tr>
    <tr>
      <td>If our <font color="blue">management</font> cannot assess     Abaxis’ <font color="blue">internal <font color="blue">control over financial</font></font> reporting as <font color="blue">effective</font>, or our     in<font color="blue">dependent</font>  <font color="blue">registered public accounting firm</font> is unable to provide an     unqualified <font color="blue">attestation</font> report on such <font color="blue">assessment</font>, investor confidence and     share value may be <font color="blue">negatively impacted</font></td>
    </tr>
    <tr>
      <td>As  a  Result of New Requirements Relating to Accounting Treatment For     Employee Stock Options, We May Be Forced to Change Our Business Practices                 We <font color="blue">currently account</font> for the issuance of <font color="blue">stock options under</font> APB     Opinion Nodtta 25, “<font color="blue">Accounting for Stock Issued to Employees</font></td>
    </tr>
    <tr>
      <td>”  On <font color="blue">December </font>16,     2004, the <font color="blue">Financial Accounting Standards Board </font>issued Statement of Financial     Accounting Standards Nodtta 123 (revised 2004), Share-Based Payment (“SFAS     123R”)</td>
    </tr>
    <tr>
      <td>The new standard requires us to treat the value of the stock     <font color="blue">options granted</font> to <font color="blue">employees as</font> a <font color="blue"><font color="blue">compensation</font> expense</font></td>
    </tr>
    <tr>
      <td>In April 2005, the     <font color="blue">Securities  </font>and  <font color="blue">Exchange Commission </font>amended the <font color="blue">compliance dates</font> and,     <font color="blue">according</font>ly, we will be required to record an expense for our stock-based     <font color="blue">compensation</font> plans using the <font color="blue">fair value method beginning on</font> April 1, 2006</td>
    </tr>
    <tr>
      <td>As a result, we may decide to reduce the number of stock <font color="blue">options granted</font> to     employees or to <font color="blue">grant options</font> to <font color="blue">fewer employees</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">could affect</font> our     ability to retain <font color="blue">existing employees</font> and <font color="blue">attract qualified candidates</font> and     increase the cash <font color="blue">compensation</font> we would have to pay to them</td>
    </tr>
    <tr>
      <td>The adoption of SFAS 123R in the <font color="blue">first quarter</font> of fiscal 2007 will     have a negative effect on our earnings</td>
    </tr>
    <tr>
      <td>To minimize future <font color="blue">compensation</font>     expense that we would recognize in our <font color="blue">financial statements</font>, on <font color="blue">December </font>5,     2005,  the  <font color="blue">Board of Directors </font>of Abaxis approved full <font color="blue">acceleration</font> of     unvested  stock  options  with  an <font color="blue">exercise price</font> of dlra19dtta12 or greater     <font color="blue">previously</font> granted under the Abaxis, Inc</td>
    </tr>
    <tr>
      <td>1998 <font color="blue">Stock Option Plan </font>held by     Company officers and employees</td>
    </tr>
    <tr>
      <td>The <font color="blue">pro forma effects on net income</font> and     <font color="blue">earnings per</font> share if we had applied the <font color="blue">fair value recognition provisions</font>     of the original SFAS 123 on stock <font color="blue">compensation</font> awards (rather than applying     the <font color="blue">intrinsic value measurement provisions</font> of Opinion 25) are disclosed in     Note 1 to the enclosed <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________                 In  October 2005, our 1998 <font color="blue">Stock Option Plan </font>was amended and     <font color="blue">restated as</font> the Abaxis, Inc</td>
    </tr>
    <tr>
      <td>2005 Equity Incentive Plan, <font color="blue">which allows</font> the     Company to provide as <font color="blue">incentives</font>, stock options, stock <font color="blue">appreciation</font> rights,     stock awards (stock purchase rights and stock bonuses), restricted stock     units, performance shares, performance units, other stock-based awards and     cash-based awards</td>
    </tr>
    <tr>
      <td>The impact of this new plan on our <font color="blue">future earnings</font>     <font color="blue">depends on</font> the type of equity based <font color="blue">incentives</font> the Company grants, the     <font color="blue">vesting conditions</font> and the number of <font color="blue">awards granted</font></td>
    </tr>
    <tr>
      <td>We Must Comply With Strict And Potentially Costly Environmental Regulations                  We are subject to <font color="blue">stringent federal</font>, state and local laws, rules,     <font color="blue">regulations</font> and policies that govern the use, generation, <font color="blue">manufacture</font>,     storage, air emission, effluent discharge, handling and disposal of certain     materials and wastes</td>
    </tr>
    <tr>
      <td>In particular, we are subject to laws, rules and     <font color="blue">regulations</font> governing the handling and disposal of <font color="blue">biohazardous materials</font>     used in the <font color="blue">development</font> and testing of our products</td>
    </tr>
    <tr>
      <td>We handle and dispose     of human and <font color="blue">veterinary</font> blood samples for testing (whole blood, plasma,     serum) and we paid approximately dlra54cmam000 in fiscal 2006 to <font color="blue">comply with</font>     applicable environmental <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Although we believe that we have     <font color="blue"><font color="blue">complied with</font> applicable laws</font> and <font color="blue">regulations</font> in all material respects and     have not been required to take any action to correct any <font color="blue">noncompliance</font>, we     may have to <font color="blue">incur significant costs</font> to <font color="blue">comply with</font> environmental <font color="blue">regulations</font>     if  our  <font color="blue">manufacturing</font> to <font color="blue">commercial levels continues</font> to increase</td>
    </tr>
    <tr>
      <td>In     addition, if a <font color="blue">government</font> agency determines that we have not <font color="blue">complied with</font>     these laws, rules and <font color="blue">regulations</font>, we may have to <font color="blue">pay significant fines</font>     and/or take <font color="blue">remedial action</font> that would be expensive and we do not carry     environmental-related insurance coverage</td>
    </tr>
    <tr>
      <td>Our  Facilities And Manufacturing Operations Are Vulnerable To Natural     Disasters And Other Unexpected Losses; System Failures Or Delays May Harm     Our Business                 Our success <font color="blue">depends on</font> the <font color="blue">efficient</font> and <font color="blue">uninterrupted operation</font>     of our <font color="blue">manufacturing</font> <font color="blue">operations</font>, which are co-located with our corporate     <font color="blue">headquarters</font>  in  Union  City, California</td>
    </tr>
    <tr>
      <td>A failure of <font color="blue">manufacturing</font>     <font color="blue">operations</font>, be it in the <font color="blue">development</font> and <font color="blue">manufacturing</font> of our Piccolo or     VetScan <font color="blue">analyzers</font> or the <font color="blue"><font color="blue">reagent disc</font>s</font> used in the <font color="blue">analyzers</font>, could result     in our <font color="blue">inability</font> to <font color="blue">supply customer demand</font></td>
    </tr>
    <tr>
      <td>We  do  not  have  a  backup  <font color="blue">facility</font>  to <font color="blue">provide redundant</font>     <font color="blue">manufacturing</font> capacity in the event of a <font color="blue">system failure</font></td>
    </tr>
    <tr>
      <td>Accordingly, if     our <font color="blue">Union City </font>location experienced a <font color="blue">system failure</font>, or <font color="blue">regulatory</font> problem     that temporarily shut-down our <font color="blue">manufacturing</font> <font color="blue">facility</font>, our <font color="blue">manufacturing</font>     <font color="blue">ability would become unavailable until</font> we were able to bring an <font color="blue">alternative</font>     <font color="blue">facility</font> online, a <font color="blue">process which could</font> take <font color="blue">several weeks</font> or <font color="blue">even months</font></td>
    </tr>
    <tr>
      <td>These  <font color="blue">manufacturing</font>  <font color="blue">operations</font>  are  also  vulnerable to <font color="blue">damage from</font>     <font color="blue">earthquakes</font>,  fire,  floods,  power loss, telecommunications failures,     break-ins and similar events</td>
    </tr>
    <tr>
      <td>Although we carry property and business     <font color="blue">interruption</font> insurance, our <font color="blue">coverage may</font> not be adequate to <font color="blue">compensate us</font>     for all losses that may occur</td>
    </tr>
    <tr>
      <td>Additionally, our <font color="blue">computer servers may</font> be     vulnerable to computer viruses, physical or electronic break-ins and similar     <font color="blue">disruption</font>s</td>
    </tr>
    <tr>
      <td>Fluctuations In Foreign Exchange Rates And The Possible Lack Of Financial     Stability In Foreign Countries Could Prevent Overseas Sales Growth                 Our  <font color="blue">international</font>  sales  are <font color="blue">overwhelmingly currently</font> US     dollar-<font color="blue">denominated</font></td>
    </tr>
    <tr>
      <td>As a result, an increase in the value of the US     dollar  relative  to  foreign  <font color="blue">currencies could</font> make our <font color="blue">products less</font>     <font color="blue">competitive</font> in <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>For the limited amount of our sales     <font color="blue">denominated</font> in local currencies, we are subject to <font color="blue"><font color="blue">fluctuation</font>s</font> in exchange     rates  between the US dollar and the <font color="blue">particular local currency</font></td>
    </tr>
    <tr>
      <td>Our     operating results <font color="blue">could also</font> be <font color="blue">adversely</font> <font color="blue">affected by</font> the <font color="blue">seasonality</font> of     <font color="blue">international</font> sales and the <font color="blue">economic conditions</font> of our <font color="blue">overseas markets</font></td>
    </tr>
    <tr>
      <td>Our Stock Price Is Highly Volatile And Investing In Our Stock Involves A     High Degree Of Risk                 The <font color="blue">market price</font> of our <font color="blue">common stock</font>, like the securities of many     other medical products companies, fluctuates over a wide range, and will     continue to be <font color="blue">highly volatile</font> in the future</td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors may affect</font> the <font color="blue">market price</font>     of our <font color="blue">common stock</font>:                                         •                       <font color="blue">fluctuation</font> in our operating results;                                             •     <font color="blue">announcements</font> of <font color="blue">technological innovations</font> or new commercial <font color="blue">products by</font> us                              or our <font color="blue">competitors</font>;                                         22     ______________________________________________________________________                                         •                        changes in <font color="blue">government</font>al regulation;                                             •                  prospects and proposals for <font color="blue">health care reform</font>;                                             •      <font color="blue">government</font>al or <font color="blue">third party</font> payors’ controls on prices that our customers                           may pay for our products;                                             •     <font color="blue">development</font>s or <font color="blue">disputes concerning patent</font> or our other <font color="blue">proprietary</font> rights;                                             •     public concern as to the safety of our devices or similar devices developed                            by our <font color="blue">competitors</font>; and                                             •                             <font color="blue">general market conditions</font></td>
    </tr>
    <tr>
      <td>Because our stock price is so volatile, investing in our common     stock is <font color="blue">highly risky</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">potential investor must</font> be able to withstand the     loss of his <font color="blue">entire investment</font> in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our Shareholders Rights Plan And Our Ability To Issue Preferred Stock May     Delay Or Prevent A Change Of Control Of <font color="blue">Abaxis     </font>            Our Shareholder Rights Plan, <font color="blue">adopted by</font> our <font color="blue">Board of Directors </font>on     April 22, 2003, may make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire, or     discourage a <font color="blue">third party</font> from attempting to acquire control of Abaxis</td>
    </tr>
    <tr>
      <td>The     Shareholder  Rights Plan <font color="blue">could limit</font> the price that investors might be     willing to pay in the future for shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">Board of Directors </font>has the authority to issue up     to 5cmam000cmam000 shares of <font color="blue">preferred stock</font> and to determine the price, rights,     preferences, privileges and <font color="blue">restrictions</font>, including <font color="blue">voting rights</font>, of those     <font color="blue">shares without</font> any <font color="blue">further vote</font> or <font color="blue">action by</font> the <font color="blue">shareholders</font>, except to the     extent required by NASDAQ rules</td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">preferred stock</font>, while     <font color="blue">providing flexibility</font> in <font color="blue">connection with possible financings</font> or <font color="blue">acquisitions</font>     or  other  corporate purposes, could have the effect of making it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of our <font color="blue">outstanding voting</font>     stock</td>
    </tr>
  </tbody>
</table>